{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:48:39Z","timestamp":1790707719886,"version":"4.1.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:sec><jats:title>Purpose of review<\/jats:title><jats:p>New research continues to provide important insights into the utility of antibody specificities. This review provides an update of recent findings, and the important insights they provide into disease mechanism.<\/jats:p><\/jats:sec><jats:sec><jats:title>Recent findings<\/jats:title><jats:p>A growing number of autoantibodies have been discovered in scleroderma patients with unique clinical associations. A subgroup of these antibodies may have functional consequences and contribute to disease pathogenesis, driving the vascular and fibrotic phenotype. Recent research into the relationship between malignancy and scleroderma onset provides important new insights into disease mechanism, and highlights the utility of autoantibodies as unique research probes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>Continued advances in the study of scleroderma antibody specificities has led to important insights into disease pathogenesis and clinical subgrouping. These advances include newly described specificities, functional antibodies and an emerging understanding of the cancer\u2013scleroderma relationship.<\/jats:p><\/jats:sec>","DOI":"10.1097\/bor.0000000000000550","type":"journal-article","created":{"date-parts":[[2018,8,27]],"date-time":"2018-08-27T01:20:21Z","timestamp":1535332821000},"page":"548-553","source":"Crossref","is-referenced-by-count":32,"title":["An update on autoantibodies in scleroderma"],"prefix":"10.1097","volume":"30","author":[{"given":"Christopher A.","family":"Mecoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Casciola-Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230901","doi-asserted-by":"crossref","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"R2-20230901","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1002\/art.27549","article-title":"Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I\/III antibodies","volume":"62","author":"Shah","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R3-20230901","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/art.38928","article-title":"Review: cancer-induced autoimmunity in the rheumatic diseases","volume":"67","author":"Shah","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R4-20230901","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1126\/science.1246886","article-title":"Association of the autoimmune disease scleroderma with an immunologic response to cancer","volume":"343","author":"Joseph","year":"2014","journal-title":"Science"},{"key":"R5-20230901","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3899\/jrheum.160817","article-title":"Malignancies in patients with anti-RNA polymerase III antibodies and systemic sclerosis: analysis of the EULAR Scleroderma Trials and Research Cohort and possible recommendations for screening","volume":"44","author":"Lazzaroni","year":"2017","journal-title":"J Rheumatol"},{"key":"R6-20230901","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.3899\/jrheum.101144","article-title":"Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies","volume":"38","author":"Airo\u2019","year":"2011","journal-title":"J Rheumatol"},{"key":"R7-20230901","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1186\/ar4486","article-title":"Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma","volume":"16","author":"Moinzadeh","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"R8-20230901","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1136\/annrheumdis-2018-212999","article-title":"Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer","volume":"77","author":"Igusa","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R9-20230901","doi-asserted-by":"crossref","first-page":"E7526","DOI":"10.1073\/pnas.1615990113","article-title":"Systematic autoantigen analysis identifies a distinct subtype of scleroderma with coincident cancer","volume":"113","author":"Xu","year":"2016","journal-title":"Proc Natl Acad Sci"},{"key":"R10-20230901","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/art.40065","article-title":"Brief report: anti-RNPC-3 Antibodies as a marker of cancer-associated scleroderma","volume":"69","author":"Shah","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R11-20230901","doi-asserted-by":"crossref","first-page":"e3931","DOI":"10.1097\/MD.0000000000003931","article-title":"Subspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease","volume":"95","author":"Perosa","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"R12-20230901","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.autrev.2014.11.007","article-title":"Autoantibodies to the mitochondrial RNA processing (MRP) complex also known as Th\/To autoantigen","volume":"14","author":"Mahler","year":"2015","journal-title":"Autoimmun Rev"},{"key":"R13-20230901","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1002\/art.39755","article-title":"Brief report: anti-eukaryotic initiation factor 2B autoantibodies are associated with interstitial lung disease in patients with systemic sclerosis","volume":"68","author":"Betteridge","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R14-20230901","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/acr.22163","article-title":"Autoantibodies to RuvBL1 and RuvBL2: a novel systemic sclerosis-related antibody associated with diffuse cutaneous and skeletal muscle involvement","volume":"66","author":"Kaji","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R15-20230901","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jsb.2011.09.001","article-title":"Structural and functional insights into a dodecameric molecular machine - the RuvBL1\/RuvBL2 complex","volume":"176","author":"Gorynia","year":"2011","journal-title":"J Struct Biol"},{"key":"R16-20230901","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/rheumatology\/kex458","article-title":"Presence of antieukaryotic initiation factor-2B, anti-RuvBL1\/2 and antisynthetase antibodies in patients with antinuclear antibody negative systemic sclerosis","volume":"57","author":"Pauling","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"R17-20230901","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.autrev.2018.01.006","article-title":"Bicaudal D2 is a novel autoantibody target in systemic sclerosis that shares a key epitope with CENP-A but has a distinct clinical phenotype","volume":"17","author":"Fritzler","year":"2018","journal-title":"Autoimmun Rev"},{"key":"R18-20230901","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/rheumatology\/keq372","article-title":"Detection of anti-IFI16 antibodies by ELISA: clinical and serological associations in systemic sclerosis","volume":"50","author":"Costa","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"R19-20230901","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/acr.22632","article-title":"Association of antibodies to interferon-inducible protein-16 with markers of more severe disease in primary Sj\u00f6gren's syndrome","volume":"68","author":"Baer","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R20-20230901","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/art.39558","article-title":"Anti-interferon-inducible protein 16 antibodies associate with digital gangrene in patients with scleroderma","volume":"68","author":"McMahan","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R21-20230901","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1089\/107999002320271413","article-title":"Immunohistochemical expression analysis of the human interferon-inducible gene IFI16, a member of the HIN200 family, not restricted to hematopoietic cells","volume":"22","author":"Gariglio","year":"2002","journal-title":"J Interferon Cytokine Res"},{"key":"R22-20230901","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/acr.22978","article-title":"Risk of digital vascular events in scleroderma patients who have both anticentromere and anti-interferon-inducible protein 16 antibodies","volume":"69","author":"McMahan","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R23-20230901","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.autrev.2017.07.019","article-title":"Role of antireceptor autoantibodies in pathophysiology of scleroderma","volume":"16","author":"Berger","year":"2017","journal-title":"Autoimmun Rev"},{"key":"R24-20230901","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/ar4457","article-title":"Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis","volume":"16","author":"Kill","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"R25-20230901","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.autrev.2016.04.004","article-title":"Antibodies against angiotensin II type 1 receptor (AT1R) and endothelin receptor type A (ETAR) in systemic sclerosis (SSc)-response","volume":"15","author":"Riemekasten","year":"2016","journal-title":"Autoimmun Rev"},{"key":"R26-20230901","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1164\/rccm.201403-0442OC","article-title":"Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis","volume":"190","author":"Becker","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"R27-20230901","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.3899\/jrheum.150061","article-title":"Autoantibodies against endothelin 1 type a receptor are strong predictors of digital ulcers in systemic sclerosis","volume":"42","author":"Avouac","year":"2015","journal-title":"J Rheumatol"},{"key":"R28-20230901","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00296-016-3639-4","article-title":"Antiangiotensin II type 1 receptor autoantibodies (AT1R-AAs) in patients with systemic sclerosis: lack of association with disease manifestations","volume":"37","author":"\u0130lgen","year":"2017","journal-title":"Rheumatol Int"},{"key":"R29-20230901","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.imlet.2017.10.007","article-title":"Agonistic antibodies in systemic sclerosis","volume":"195","author":"Moroncini","year":"2018","journal-title":"Immunol Lett"},{"key":"R30-20230901","doi-asserted-by":"crossref","first-page":"G1052","DOI":"10.1152\/ajpgi.00034.2016","article-title":"Role of muscarinic-3 receptor antibody in systemic sclerosis: correlation with disease duration and effects of IVIG","volume":"310","author":"Kumar","year":"2016","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R31-20230901","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/art.39728","article-title":"Induction of scleroderma fibrosis in skin-humanized mice by administration of anti-platelet-derived growth factor receptor agonistic autoantibodies","volume":"68","author":"Luchetti","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R32-20230901","first-page":"75","article-title":"Agonistic anti-PDGF receptor autoantibodies from patients with systemic sclerosis impact human pulmonary artery smooth muscle cells function in vitro","volume":"8","author":"Svegliati","year":"2017","journal-title":"Front Immunol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201811000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T15:25:31Z","timestamp":1751815531000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201811000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000550","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}